To investigate the effect of CD83 overexpression on antitumor efficacy of CAR-T cells in vivo, we infused mesothelin-targeting CAR-T cells with or without ectopic expression of CD83 into NSG mice that were subcutaneously inoculated with the mesothelin-expressing pancreatic cancer cell line AsPC-1 (Fig. 5i). The gene discussed is MSLN; the disease is familial pancreatic carcinoma.